Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Epstein-Peterson ZD, Drill E, Aypar U, Batlevi CL, Caron P, Dogan A, Drullinsky P, Gerecitano J, Hamlin PA, Ho C, Jacob A, Joseph A, Laraque L, Matasar MJ, Moskowitz AJ, Moskowitz CH, Mullins C, Owens C, Salles G, Schöder H, Straus DJ, Younes A, Zelenetz AD, Kumar A.
Epstein-Peterson ZD, et al. Among authors: mullins c.
Haematologica. 2024 Apr 1;109(4):1149-1162. doi: 10.3324/haematol.2023.282898.
Haematologica. 2024.
PMID: 37646671
Free PMC article.
Clinical Trial.